Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Immunogenicity of CT-P55 vs Cosentyx in Healthy Males
NCT07054970Phase 1Completed
- Sponsor
- Celltrion
- Start
- Jan 2024
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CT-P55 in plaque psoriasis (3 arms), sponsored by Celltrion. Primary endpoints: Area under the concentration-time curve from time zero to infinity at Day 155 and Maximum serum concentration at Day 155. Started Jan 2024; status: completed.
02
Drugs
CT-P55
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07054970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054970.